Cingulate Q3 net loss widens 5% to $7.73 million
CING•Cingulate's third-quarter net loss widened 5% year over year to $7.73 million. The company had $23.19 million in cash at September 30, 2026, and expected it to fund operations into mid-2027.
1. Quarterly results and outlook
Cingulate's selling, general and administrative expenses rose 46% to $4.58 million, driven by expanded commercial readiness capabilities. Manufacturing remediation for CTx-1301 was substantially complete, and the company expected to resubmit its NDA between December 2026 and January 2027. The FDA's Complete Response Letter requested additional manufacturing information but raised no clinical safety or efficacy concerns.
